Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b4 + BNT162b2 COVID-19 vaccine in healthy adults
NCT05541861Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BNT162b4 in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by BioNTech SE. Primary endpoints: Number of Participants With Solicited Local Reactions at 7 days, Number of Participants With Solicited Systemic Events at 7 days and 7 more. Started Nov 2022; status: completed.
02
Drugs
BNT162b4
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05541861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541861.